Tea catechins as inhibitors of receptor tyrosine kinases: Mechanistic insights and human relevance

Pharmacological Research

Volumn 62, Issue 6, 2010, Pages 457-464

  Larsen, Christine A ^a   Dashwood, Roderick H ^a,b   Bisson, William H ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Green tea polyphenols; Hepatocyte growth factor; Met signaling; Receptor tyrosine kinases

Indexed keywords

AXITINIB; CATECHIN; CELL PROTEIN; EPICATECHIN; EPICATECHIN GALLATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPHENOL DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER CELL; CANCER MODEL; CANCER PREVENTION; CANCER THERAPY; CARCINOGENICITY; CELL DEATH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PLEIOTROPY; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TEA; VOMITING;

ANIMALS; ANTICARCINOGENIC AGENTS; CATECHIN; HUMANS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; TEA;

EID: 78049528044     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.07.010     Document Type: Review

References (104)

1. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009, 9:429-439.
2. Ferruzzi M.G. The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol Behav 2010, 100:33-41.
3. Higdon J.V., Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003, 43:89-143.
4. Wang Y., Ho C.T. Polyphenolic chemistry of tea and coffee: a century of progress. J Agric Food Chem 2009, 57:8109-8114.
5. Ju J., Lu G., Lambert J.D., Yang C.S. Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol 2007, 17:395-402.
6. Santana-Rios G., Orner G.A., Amantana A., Provost C., Wu S.Y., Dashwood R.H. Potent antimutagenic activity of white tea in comparison with green tea in the Salmonella assay. Mutat Res 2001, 495:61-74.
7. Kohri T., Nanjo F., Suzuki M., Seto R., Matsumoto N., Yamakawa M., et al. Synthesis of (-)-[4-3H]epigallocatechin gallate and its metabolic fate in rats after intravenous administration. J Agric Food Chem 2001, 49:1042-1048.
8. Lambert J.D., Lee M.J., Lu H., Meng X., Hong J.J., Seril D.N., et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003, 133:4172-4177.
9. Li C., Meng X., Winnik B., Lee M.J., Lu H., Sheng S., et al. Analysis of urinary metabolites of tea catechins by liquid chromatography/electrospray ionization mass spectrometry. Chem Res Toxicol 2001, 14:702-707.
10. Lambert J.D., Sang S., Yang C.S. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm 2007, 4:819-825.
11. Kim S., Lee M.J., Hong J., Li C., Smith T.J., Yang G.Y., et al. Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr Cancer 2000, 37:41-48.
12. Chen L., Lee M.J., Li H., Yang C.S. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 1997, 25:1045-1050.
13. Natsume M., Osakabe N., Oyama M., Sasaki M., Baba S., Nakamura Y., et al. Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free Radic Biol Med 2003, 34:840-849.
14. Van Amelsvoort J.M., Van Hof K.H., Mathot J.N., Mulder T.P., Wiersma A., Tijburg L.B. Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica 2001, 31:891-901.
15. Ullmann U., Haller J., Decourt J.P., Girault N., Girault J., Richard-Caudron A.S., et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003, 31:88-101.
16. Stalmach A., Mullen W., Steiling H., Williamson G., Lean M.E., Crozier A. Absorption, metabolism, and excretion of green tea flavan-3-ols in humans with an ileostomy. Mol Nutr Food Res 2010, 54:323-334.
17. Hou Z., Lambert J.D., Chin K.V., Yang C.S. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 2004, 555:3-19.
18. Lambert J.D., Hong J., Yang G.Y., Liao J., Yang C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005, 81:284S-291S.
19. Yang C.S., Lambert J.D., Hou Z., Ju J., Lu G., Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 2006, 45:431-435.
20. Orner G.A., Dashwood W.M., Blum C.A., Diaz G.D., Li Q., Dashwood R.H. Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003, 24:263-267.
21. Brown M.D. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern Med Rev 1999, 4:360-370.
22. Katiyar S.K., Mukhtar H. Tea consumption and cancer. World Rev Nutr Diet 1996, 79:154-184.
23. Kohlmeier L., Weterings K.G., Steck S., Kok F.J. Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer 1997, 27:1-13.
24. Yang C.S., Wang Z.Y. Tea and cancer. J Natl Cancer Inst 1993, 85:1038-1049.
25. Yang C.S., Lambert J.D., Ju J., Lu G., Sang S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 2007, 224:265-273.
26. Yang C.S., Maliakal P., Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002, 42:25-54.
27. Chacko S.M., Thambi P.T., Kuttan R., Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med 2010, 5:13.
28. Tsubono Y., Nishino Y., Komatsu S., Hsieh C.C., Kanemura S., Tsuji I., et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001, 344:632-636.
29. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
30. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 14:1117-1134.
31. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010, 1802:396-405.
32. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N., et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997, 11:701-713.
33. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
34. Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
35. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
36. Richmond A. NF-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2:664-674.
37. Dhawan P., Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002, 277:7920-7928.
38. Albanese C., Johnson J., Watanabe G., Eklund N., Vu D., Arnold A., et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995, 270:23589-23597.
39. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19:5785-5799.
40. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002, 68-69:95-114.
41. Shishodia A., Aggarwal B.B. Nuclear factor-kappaB: a friend or a foe in cancer?. Biochem Pharmacol 2004, 68:1071-1080.
42. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
43. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
44. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
45. Gennigens C., Menetrier-Caux C., Droz J.P. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006, 58:124-145.
46. Donovan E.A., Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008, 66:91-98.
47. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005, 92:2097-2101.
48. Huynh H., Chow P.K., Ooi L.L., Soo K.C. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002, 13:115-122.
49. Shimizu M., Shirakami Y., Sakai H., Tatebe H., Nakagawa T., Hara Y., et al. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett 2007, 262:10-18.
50. Li M., He Z., Ermakova S., Zheng D., Tang F., Cho Y.Y., et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 2007, 16:598-605.
51. Liang Y.C., Lin-shiau S.Y., Chen C.F., Lin J.K. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997, 67:55-65.
52. Fuand Y., Chen A. The phytochemical (-)-epigallocatechin gallate suppresses gene expression of epidermal growth factor receptor in rat hepatic stellate cells in vitro by reducing the activity of Egr-1. Biochem Pharmacol 2006, 72:227-238.
53. Chin V., Yang C.S. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005, 65:8049-8056.
54. Dashwood W.M., Orner G.A., Dashwood R.H. Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H2O2 at physiologically relevant EGCG concentrations. Biochem Biophys Res Commun 2002, 296:584-588.
55. Adachi S., Nagao T., To S., Joe A.K., Shimizu M., Matsushima-Nishiwaki R., et al. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008, 29:1986-1993.
56. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003, 28:488-494.
57. Ng Y.S., Krilleke D., Shima D.T. VEGF function in vascular pathogenesis. Exp Cell Res 2006, 312:527-537.
58. Lee Y.K., Bone N.D., Strege A.K., Shanafelt T.D., Jelinek D.F., Kay N.E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004, 104:788-794.
59. Kondo T., Ohta T., Igura K., Hara Y., Kaji K. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett 2002, 180:139-144.
60. Shirakami Y., Shimizu M., Adachi S., Sakai H., Nakagawa T., Yasuda Y., et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009, 100:1957-1962.
61. Ahn H.Y., Hadizadeh K.R., Seul C., Yun Y.P., Vetter H., Sachinidis A. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell 1999, 10:1093-1104.
62. Sachinidis A., Seul C., Seewald S., Ahn H., Ko Y., Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett 2000, 471:51-55.
63. Sachinidis A., Skach R.A., Seul C., Ko Y., Hescheler J., Ahn H.Y., et al. Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins. FASEB J 2002, 16:893-895.
64. Suzuki Y., Hattori S., Isemura M. Epigallocatechin-3-O-gallate inhibits fibroblast contraction of floating collagen gel: interaction between epigallocatechin-3-O-gallate and platelet derived growth factor. Biosci Biotechnol Biochem 2004, 68:1817-1820.
65. Weber A.A., Neuhaus T., Skach R.A., Hescheler J., Ahn H.Y., Schror K., et al. Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis. FASEB J 2004, 18:128-130.
66. Naran S., Zhang X., Hughes S.J. Inhibition of HGF/MET as therapy for malignancy. Expert Opin Ther Targets 2009, 13:569-581.
67. Ma P.C., Maulik G., Christensen J., Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003, 22:309-325.
68. Bigelow R.L., Cardelli J.A. The green tea catechins, (-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006, 25:1922-1930.
69. Larsen C.A., Bisson W.H., Dashwood R.H. Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. J Med Chem 2009, 52:6543-6545.
70. Larsen C.A., Dashwood R.H. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys 2010, March 31 [Epub ahead of print].
71. Sah J.F., Balasubramanian S., Eckert R.L., Rorke E.A. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of RK1/2 and AKT kinases. J Biol Chem 2004, 279:12755-12762.
72. Long L.H., Clement M.V., Halliwell B. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate (+)-catechin, and quercetin to commonly used cell culture media. Biochem Biophys Res Commun 2000, 273:50-53.
73. Hashigasako A., Machide M., Nakamura T., Matsumoto K., Nakamura T. Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J Biol Chem 2004, 279:26445-26452.
74. Larsen C.A., Dashwood R.H. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. Biochem Biophys Res Commun 2009, 389:527-530.
75. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998, 14:111-136.
76. Prinetti A., Chigorno V., Tettamanti G., Sonnino S. Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. J Biol Chem 2000, 275:11658-11665.
77. Pike L.J., Han X., Gross R.W. Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids: a shotgun lipidomics study. J Biol Chem 2005, 280:26796-26804.
78. Remacle-Bonnet M., Garrouste F., Baillat G., Andre F., Marvaldi J., Pommier G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 2005, 167:761-773.
79. Pike L.J., Casey L. Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 2002, 41:10315-10322.
80. Puri C., Tosoni D., Comai R., Rabellino A., Segat D., Caneva F., et al. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell 2005, 16:2704-2718.
81. Massieand C., Mills I.G. The developing role of receptors and adaptors. Nat Rev Cancer 2006, 6:403-409.
82. Teillet F., Boumendjel A., Boutonnat J., Ronot X. Flavonoids as RTK inhibitors and potential anticancer agents. Med Res Rev 2008, 28:715-745.
83. Albrecht B.K., Harmange J.C., Bauer D., Berry L., Bode C., Boezio A.A., et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008, 51:2879-2882.
84. Timofeevski S.L., McTigue M.A., Ryan K., Cui J., Zou H.Y., Zhu J.X., et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazaine inhibitors. Biochemistry 2009, 48:5339-5349.
85. Kuzuhara T., Suganuma M., Fujiki H. Green tea catechin as a chemical chaperone in cancer prevention. Cancer Lett 2008, 261:12-20.
86. Yang C.S., Sang S., Lambert J.D., Lee M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008, 52(Suppl. 1):S139-S151.
87. Sirtori C.R., Galli C., Anderson J.W., Sirtori E., Arnoldi A. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 2009, 22:244-261.
88. Grove K.A., Lambert JD Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr 2010, 140:446-453.
89. Richard D., Kefi K., Barbe U., Poli A., Bausero P., Visioli F. Weight and plasma lipid control by decaffeinated green tea. Pharmacol Res 2009, 59:351-354.
90. Kim J., Lee H.J., Lee K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 2010, 112:1415-1430.
91. Liang Y.C., Chen Y.C., Lin Y.L., Lin-Shiau S.Y., Ho C.T., Lin J.K. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate. Carcinogenesis 1999, 20:733-736.
92. Masuda M., Suzui M., Weinstein I.B. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001, 7:4220-4229.
93. Guo S., Lu J., Subramanian A., Sonenshein G.E. Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells. Cancer Res 2006, 66:5322-5329.
94. Pianetti S., Guo S., Kavanagh K.T., Sonenshein G.E. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 2002, 62:652-655.
95. Lim Y.C., Park H.Y., Hwang S.W., Kang S.U., Pyun J.H., Lee M.H., et al. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett 2008, 271:140-152.
96. Milligan S.A., Burke P., Coleman D.T., Bigelow R.L., Steffan J.J., Carroll J.L., et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009, 15:4885-4894.
97. Sakata R., Ueno T., Nakamura T., Sakamoto M., Torimura T., Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 2004, 40:52-59.
98. Park J.S., Kim M.H., Chang H.J., Kim K.M., Kim S.M., Shin B.A., et al. Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2. Int J Oncol 2006, 29:1247-1252.
99. Chen A., Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J Biol Chem 2003, 278:23381-23389.
100. Murphy C.C., Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology 2010, 24:410-415.
101. Ren H., Yang B.F., Rainov N.G. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials 2007, 2:87-101.
102. Wolter P., Schöffski P. Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol 2010, 49:13-23.
103. Papaetis G.S., Syrigo K.N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009, 23:377-389.
104. Kelly R.J., Rixe O. Axitinib (AG-013736). Recent Results Cancer Res 2010, 184:33-44.